ALTIMMUNE, INC. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
ALTIMMUNE, INC. (ALT) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $3.44 million as of 2025-12-31, per its 10-K filed 2026-03-06.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-03-06
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $3.44M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $3.53M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $2.79M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $2.19M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost as first filed |
|---|---|---|
| 2025-12-31 | $3.44M 10-K · filed 2026-03-06 | |
| 2024-12-31 | $3.53M 10-K · filed 2026-03-06 | |
| 2023-12-31 | $2.79M 10-K · filed 2025-02-27 | |
| 2022-12-31 | $2.19M 10-K · filed 2024-03-27 | |
| 2021-12-31 | $1.28M 10-K · filed 2023-02-28 | $1.28M 10-K · filed 2022-03-15 |
| 2020-12-31 | $584.51K 10-K · filed 2022-03-15 | |
| 2019-12-31 | $622.79K 10-K · filed 2021-02-25 | |
| 2018-12-31 | $568.16K 10-K · filed 2020-03-27 | |
| 2017-12-31 | $589.99K 10-K · filed 2019-04-01 | |
| 2016-12-31 | $561.75K 10-K · filed 2018-04-02 | $1.41M 10-K · filed 2017-03-14 |
| 2015-12-31 | $2.35M 10-K · filed 2017-03-14 | |
| 2014-12-31 | $3.46M 10-K · filed 2017-03-14 | |
| 2013-12-31 | $3.37M 10-K · filed 2016-03-11 | |
| 2012-12-31 | $3.05M 10-K · filed 2015-03-11 | |
| 2011-12-31 | $2.61M 10-K · filed 2013-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |